ArticleBMC pregnancy and childbirth2025
Evaluation of the effects of indomethacin tocolytic treatment on fetal heart using modified myocardial performance index (Mod-MPI).
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndomethacin is one of the most effective and widely used tocolytic agents for treating threatened preterm labor and prolonging pregnancy. Nonetheless, data on its fetal effects, particularly regarding cardiac functions, remain limited. The primary aim of this study was to evaluate the effects of indomethacin treatment on fetal cardiac structures, the modified myocardial performance index (Mod-MPI), and hemodynamic parameters to establish evidence-based monitoring recommendations in cases of threatened preterm labor.
methodsIn this prospective study of 114 pregnant women, 57 cases diagnosed with threatened preterm birth received indomethacin tocolytic therapy, while 57 controls had uneventful pregnancies. Demographic characteristics, perinatal outcomes, Doppler measurements, cardiac structural measurements, Mod-MPI, and tricuspid regurgitation were compared between groups.
resultsDoppler analysis revealed no significant differences except for umbilical artery pulsatility index, which was elevated in the indomethacin group (0.941 ± 0.160 vs. 0.869 ± 0.171, p = 0.023) due to vasoconstrictive effects from prostaglandin synthesis inhibition. Isovolumetric contraction and relaxation times were lower in the indomethacin group (42.3 ± 0.5 vs. 47.2 ± 2.7, p = 0.020; 49.3 ± 1.9 vs. 48.2 ± 1.8, p = 0.030). However, Mod-MPI did not differ significantly between the groups (0.464 ± 0.11 vs. 0.44 ± 0.09, p = 0.349). Although tricuspid regurgitation was observed in 14 of 57 fetuses (24.6%) exposed to indomethacin, perinatal outcomes were not significantly different.
conclusionsIndomethacin treatment does not negatively affect fetal cardiac function or Mod-MPI. When tricuspid regurgitation occurs, increased monitoring is recommended rather than treatment cessation if other parameters remain stable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.